News Center

Featured

ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio...

The acquisition of ValenzaBio adds multiple clinical and pre-clinical development programs to ACELYRIN’s robust immunology pipeline, which is led by izokibep.

Read More Arrow purple
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa
Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
ACELYRIN, INC. Hosts KOL Panel Discussion at ACR Convergence 2022 on Role of Enthesitis in PsA and AxSpA
ACELYRIN, INC. Adds Two Veteran C-suite Leaders
ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function
ACELYRIN, INC. to Present at Upcoming Investor Conferences
ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases
ACELYRIN, INC. Appoints Biotechnology Veteran Gil M. Labrucherie as Chief Financial Officer
ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress